To provide a theoretical basis for developing anti‐tumor drugs by targeting SUCLG2, we depleted endogenous SUCLG2 and stably reintroduced wild‐type SUCLG2 (SUCLG2WT) or the SUCLG2K93R mutant into A549 cells (Figure 8E). The gene discussed is SUCLG2; the disease is neoplasm.